Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) ("Altrova Health" or the "Company") today announced the introduction of O-Spray™, a needle-free sublingual oral spray dosage format designed as an alternative to self-injection, pill, and syringe-based administration. O-Spray is positioned across current and future therapeutic areas including weight management, erectile dysfunction, menopause-related care, and other indications where an oral spray format may be appropriate.

Market Context

The global GLP-1 receptor agonist market was valued at approximately USD 53.5 billion in 2024 and is projected to reach approximately USD 315 billion by 2035 at a CAGR of 17.5%.¹ In Canada, the market generated approximately USD 2.1 billion in 2025 and is projected to reach USD 6.6 billion by 2033 at a CAGR of 14.2%.² Despite this scale, injectable administration accounted for approximately 83% of global GLP-1 market share by route of administration in 2024, while the oral and alternative delivery segment is projected to be the fastest-growing category going forward.³ O-Spray dosage formats supports prescription-based sublingual alternatives within this context.

About O-Spray

O-Spray utilizes an airless metered-dose pump that delivers a precise, consistent dose with each actuation. The format requires no needles, preparation, refrigeration, or mixing. Administration involves a quick spray under the tongue, a ten-minute absorption window, and no further steps.

Key format features include:

• Airless pump technology maintaining formulation stability and consistent dosing

• Compact, discreet design suitable for daily carry; shelf-stable at room temperature

The dosage format is a documented consideration in patient engagement. A Canadian study published in Vaccine found that approximately 24% of adults report a fear of needles, and a 2022 global survey of 2,098 adults published in PLOS One found that 94.1% of needle-phobic respondents identified non-invasive device alternatives as their preferred mitigation approach.^4,5

O-Spray is designed to support healthcare-professional discussions for patients where administration method is a relevant factor in their care decisions. For more information, visit www.o-spray.com.

Management Commentary

"The introduction of O-Spray represents an important step in Altrova Health's strategy to deliver accessible delivery formats across high-demand therapeutic categories," said Geoff Benic, Chief Executive Officer of Altrova Health "We believe the combination of a needle-free sublingual format with a metered-dose system engineered for precision and ease of use addresses a real and underserved dimension of patient preference."

"O-Spray reflects our commitment to building a health platform that meets patients where they are," said Raf Souccar, Chairman of the Board of Altrova Health "Administration format meaningfully affects how people engage with their treatment. By offering a needle-free, discreet alternative, we believe O-Spray can support stronger patient-provider conversations and broaden access to care for individuals who may otherwise delay or avoid treatment."

Update on Healthy Sprays Agreement

The Company also wishes to advise that it has mutually agreed with Healthy Sprays LLC ("Healthy Sprays") to terminate the Exclusive Territory License and Commercial Agreement dated November 21, 2025 (the "Healthy Sprays Agreement"), which was previously announced by the Company on November 24, 2025. Pursuant to a settlement agreement and mutual release entered into between the parties, the Healthy Sprays Agreement has been rescinded in its entirety and the parties have exchanged full and final mutual releases. No additional payments were made by either party in connection with the termination. The Company has no further commercial obligations to Healthy Sprays, and Healthy Sprays has no further commercial obligations to the Company.

About Altrova Health Inc.

Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA ("NIRLAB") NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection product line, and the O-Spray product line.

For more information, please visit www.altrovahealth.com.

On behalf of the Board of Directors of Altrova Health Inc.

"Geoff Benic"
Geoff Benic, CEO

1 Towards Healthcare. 2026. "GLP-1 Receptor Agonist Market Size, Share and Forecast, 2025–2035." Accessed May 2026. https://www.towardshealthcare.com/insights/glp-1-receptor-agonist-market-sizing.
2 Grand View Research / Horizon Databook. 2025. "Canada GLP-1 Receptor Agonist Market Size & Outlook, 2033." Accessed May 2026. https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/canada.
3 Towards Healthcare. 2026. "GLP-1 Drugs Market Size, Recent Updates and Industrial Statistics." Accessed May 2026. https://www.towardshealthcare.com/insights/glp1-drugs-market-sizing.
4 Taddio, Anna, Moshe Ipp, Sonia Thivakaran, Alana Jamal, Charu Parikh, Cheryl Smart, Joanne Sovran, Dennis Stephens, and Joel Katz. 2012. "Survey of the Prevalence of Immunization Non-Compliance Due to Needle Fears in Children and Adults." Vaccine 30 (32): 4807–12. https://www.sciencedirect.com/science/article/abs/pii/S0264410X1200686X.
5 Ruiz Echarri, Manuel, Enrique Baca-Garcia, Maria Dolores Braquehais, and Jose de Leon. 2022. "Prevalence, Causes, Impacts, and Management of Needle Phobia: An International Survey of a General Adult Population." PLOS One 17 (11): e0276814. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0276814.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking information"). Forward-looking information can generally be identified by the use of words such as "plans," "expects," "intends," "anticipates," "believes," "estimates," "may," "will," "could," "would," "should," "looks forward to," or variations of such words, or statements that certain events or conditions "may" or "will" occur.

Forward-looking information in this press release includes, but is not limited to, statements regarding: the Company's plans and expectations with respect to the launch, commercialization, and market acceptance of the O-Spray product line; the anticipated growth of the GLP-1 receptor agonist market and the oral and alternative delivery segment; the Company's business strategy, objectives, and product pipeline; and the Company's ability to execute on its product development and commercialization plans following the termination of the Healthy Sprays Agreement.

This press release also contains market data and industry forecasts obtained from third-party sources. Such data involves assumptions and limitations, is inherently forward-looking, and actual market conditions may differ materially from those projected. The Company has not independently verified such third-party data and makes no representation as to its accuracy or completeness.

Forward-looking information is based on certain assumptions, including, but not limited to: the Company's ability to successfully develop, manufacture, and commercialize the O-Spray product line; the receipt and maintenance of all necessary regulatory approvals and licences; the availability of sufficient working capital and financing to fund operations and product launches; the Company's ability to attract and retain key personnel; general market and economic conditions; and the competitive environment in which the Company operates.

Forward-looking information involves known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied, including, but not limited to: risks related to the early stage of commercialization of the O-Spray product line; regulatory risks, including the risk that required Health Canada or other regulatory approvals may not be obtained or maintained; the Company's limited operating history and history of losses; the Company's reliance on a small number of products and distribution relationships; risks related to the Company's financial condition, including the going-concern qualification in its most recent audited financial statements; the ability to obtain additional financing on acceptable terms; competition from larger, better-capitalized competitors; general economic and market conditions; and other risks described in the Company's public disclosure documents filed on SEDAR+ at www.sedarplus.ca.

The forward-looking information contained in this press release is made as of the date hereof, and the Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295895

Source: Altrova Health Inc.